CoChat

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Significance: We recently reported that activin type II receptors (ActRIIs) blockade using bimagrumab could positively impact muscle wasting in mice and humans. However, the specific role of each individual ActRII at regulating adult muscle mass had not been clarified. Here, we highlight the importance of concomitant neutralization of both ActRIIs in controlling muscle mass. Through comparison with single specificity antibodies, we uncover unique features related to bimagrumab and its neutralizing interactions with both ActRIIA and ActRIIB at the structural and cellular levels and in vivo in adult mice. The need for simultaneous engagement and neutralization of both ActRIIs to generate a strong skeletal muscle response confers unique therapeutic potential to bimagrumab, in the context of muscle wasting conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1707925114

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Binding modalities of bimagrumab to ActRIIA and ActRIIB. Crystal structures of the bimagrumab Fv (light/dark blue ribbon) complex with (A) human ActRIIA LBD (gold ribbon) or (B) human ActRIIB LBD (red ribbon), shown in the same orientation. (C) Crystal structure of the mouse ActRIIB LBD complex with human activin-β (PDB entry 1S4Y) (35), shown in the same orientation as in A, B, and D. (D) Overlay of the ActRIIA Fv complex (gold ribbon) and ActRIIB Fv complex (red ribbon). (E) Footprint of activin (gray surface, calculated from PDB entry 1S4Y) and (F) bimagrumab on the ActRIIB LBD. Note the extensive overlap between the two binding surfaces.
Fig. 1. Binding modalities of bimagrumab to ActRIIA and ActRIIB. Crystal structures of the bimagrumab Fv (light/dark blue ribbon) complex with (A) human ActRIIA LBD (gold ribbon) or (B) human ActRIIB LBD (red ribbon), shown in the same orientation. (C) Crystal structure of the mouse ActRIIB LBD complex with human activin-β (PDB entry 1S4Y) (35), shown in the same orientation as in A, B, and D. (D) Overlay of the ActRIIA Fv complex (gold ribbon) and ActRIIB Fv complex (red ribbon). (E) Footprint of activin (gray surface, calculated from PDB entry 1S4Y) and (F) bimagrumab on the ActRIIB LBD. Note the extensive overlap between the two binding surfaces.CC BY-NC-ND · PubMed Central
Fig. 2. ActRIIA (Upper) and ActRIIB (Lower) epitope recognized by bimagrumab. The Upper part of each panel shows the number of direct intermolecular contacts between nonhydrogen atoms within a 4.0-Å distance; Lower part shows the reduction in solvent-accessible surface upon complex formation. The amino acid sequence of the respective ActRII LBD is displayed on the horizontal axis, together with a schematic representation of the secondary structure elements (arrows, β-strands; thick lines, connecting loops).
Fig. 2. ActRIIA (Upper) and ActRIIB (Lower) epitope recognized by bimagrumab. The Upper part of each panel shows the number of direct intermolecular contacts between nonhydrogen atoms within a 4.0-Å distance; Lower part shows the reduction in solvent-accessible surface upon complex formation. The amino acid sequence of the respective ActRII LBD is displayed on the horizontal axis, together with a schematic representation of the secondary structure elements (arrows, β-strands; thick lines, connecting loops).CC BY-NC-ND · PubMed Central
Fig. 3. Cellular responses to ActRIIA and ActRIIB neutralization. (A) Binding of anti-ActRIIA (CSJ089, blue), anti-ActRIIB (CQI876, orange), anti-ActRIIA and ActRIIB Abs combination (black), bimagrumab (green), or isotype control Ab (gray) to HEK293T/17 cells. (B) Efficacy/potency of antibodies or combination thereof at blocking myostatin or activin A-induced Smad2/3 response. Single-specificity Abs (CSJ089, blue), (CQI876, orange), or combination thereof (CSJ089 and CQI876, black), or bimagrumab (green, triangle) or CDD861 (green, circle) were tested for their ability to inhibit myostatin (10 ng/mL) or activin A (10 ng/mL)-induced Smad2/3 response in a CAGA-luciferase reporter gene assay in HEK293T/17 cells.
Fig. 3. Cellular responses to ActRIIA and ActRIIB neutralization. (A) Binding of anti-ActRIIA (CSJ089, blue), anti-ActRIIB (CQI876, orange), anti-ActRIIA and ActRIIB Abs combination (black), bimagrumab (green), or isotype control Ab (gray) to HEK293T/17 cells. (B) Efficacy/potency of antibodies or combination thereof at blocking myostatin or activin A-induced Smad2/3 response. Single-specificity Abs (CSJ089, blue), (CQI876, orange), or combination thereof (CSJ089 and CQI876, black), or bimagrumab (green, triangle) or CDD861 (green, circle) were tested for their ability to inhibit myostatin (10 ng/mL) or activin A (10 ng/mL)-induced Smad2/3 response in a CAGA-luciferase reporter gene assay in HEK293T/17 cells.CC BY-NC-ND · PubMed Central
Fig. 4. Hypertrophy response as measured via (A) body weight, (B) muscle weight change from sham group, after 4-wk treatment with ActRIIA-specific Ab, ActRIIB-specific Ab, combination thereof, and bimagrumab in SCID mice (n = 12 per group). Mice were untreated, sham group (white), or treated with weekly s.c. injection of isotype control antibody (20 mg/kg/wk) or of anti-ActRIIA Ab (CSJ089, blue, 6 or 20 mg/kg), an anti-ActRIIB Ab (CQI876, orange, 6 or 20 mg/kg), a combination of CSJ089 and CQI876 (black, 6 or 20 mg/kg of each Ab), or bimagrumab (green, 6 or 20 mg/kg). (C) Invasive muscle contractile function determination in gastrocnemius muscle of sham (white) and bimagrumab (green, 6 and 20 mg/kg)-treated groups, average of three stimulations. Hypertrophy response was measured through gastrocnemius and quadriceps muscle weight changes in SCID mice, (D) after 2-wk treatment with the same antibodies as in A, all dosed at 20 mg/kg, with CQI876 being also dosed at 100 mg/kg (orange crosses), (E) after 4-wk treatment with weekly s.c. injection of isotype control antibody (stripes), dual anti-ActRIIA/ActRIIB Ab (CDD861, green pattern, 20 mg/kg), and bimagrumab (green, 20 mg/kg). (F) Activin A (inhba gene) expression changes in gastrocnemius muscle of SCID mice, after 2-wk treatment with isotype control, combination of anti-ActRIIA and anti-ActRIIB Abs (black), or bimagrumab (green) as in D. (G) ELISA data for activin A level in serum from mice of D/F. Data are presented as mean ± SEM analyzed using one-way ANOVA; differences vs. control were considered statistically significant, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Unpaired t test 20 vs. 6 mg/kg, #P < 0.05.
Fig. 4. Hypertrophy response as measured via (A) body weight, (B) muscle weight change from sham group, after 4-wk treatment with ActRIIA-specific Ab, ActRIIB-specific Ab, combination thereof, and bimagrumab in SCID mice (n = 12 per group). Mice were untreated, sham group (white), or treated with weekly s.c. injection of isotype control antibody (20 mg/kg/wk) or of anti-ActRIIA Ab (CSJ089, blue, 6 or 20 mg/kg), an anti-ActRIIB Ab (CQI876, orange, 6 or 20 mg/kg), a combination of CSJ089 and CQI876 (black, 6 or 20 mg/kg of each Ab), or bimagrumab (green, 6 or 20 mg/kg). (C) Invasive muscle contractile function determination in gastrocnemius muscle of sham (white) and bimagrumab (green, 6 and 20 mg/kg)-treated groups, average of three stimulations. Hypertrophy response was measured through gastrocnemius and quadriceps muscle weight changes in SCID mice, (D) after 2-wk treatment with the same antibodies as in A, all dosed at 20 mg/kg, with CQI876 being also dosed at 100 mg/kg (orange crosses), (E) after 4-wk treatment with weekly s.c. injection of isotype control antibody (stripes), dual anti-ActRIIA/ActRIIB Ab (CDD861, green pattern, 20 mg/kg), and bimagrumab (green, 20 mg/kg). (F) Activin A (inhba gene) expression changes in gastrocnemius muscle of SCID mice, after 2-wk treatment with isotype control, combination of anti-ActRIIA and anti-ActRIIB Abs (black), or bimagrumab (green) as in D. (G) ELISA data for activin A level in serum from mice of D/F. Data are presented as mean ± SEM analyzed using one-way ANOVA; differences vs. control were considered statistically significant, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Unpaired t test 20 vs. 6 mg/kg, #P < 0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 157

Metadata

Authors
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., Koelbing, C., Leber, X., Schilb, A., Witte, F., Lehmann, S., Koch, E., Geisse, S., Glass, D. J., & Lach-Trifilieff, E.
Affiliations
  • MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;
  • Novartis Institutes for BioMedical Research (CH)
  • Novartis (Switzerland) (CH)
  • MorphoSys (Germany) (DE)
  • Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139
Venue
Proceedings of the National Academy of Sciences
Published
2017-11-06
Volume
114
Issue
47
Pages
12448-12453
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2767554184
Cited by
142
References
46
Citations by year
2026: 15 · 2025: 21 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 21 · 2020: 27 · 2019: 18 · 2018: 8
FWCI
5.92
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
  • The Novartis Repository (Novartis) (submittedVersion)
Funders
  • Paul Scherrer Institut
  • Novartis Institutes for BioMedical Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
Keywords
activin type II receptor, ActRIIA, ActRIIB, bimagrumab, myostatin, activin A, skeletal muscle hypertrophy, TGF-beta signaling, receptor antagonism, competitive binding, cachexia, muscle atrophy, GDF11
MeSH terms
Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Humans, Hypertrophy, Male, Recombinant Proteins, Signal Transduction, Mice, SCID, Rats, Wistar, Crystallography, X-Ray, Muscle, Skeletal, Antibodies, Blocking, Wasting Syndrome, Bone Morphogenetic Proteins, Activins, Activin Receptors, Type II, Mice, Rats, Growth Differentiation Factors, Myostatin, HEK293 Cells, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. https://app.cochat.ai/papers/10.1073/pnas.1707925114
The paper
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., Koelbing, C., Leber, X., Schilb, A., Witte, F., Lehmann, S., Koch, E., Geisse, S., Glass, D. J., & Lach-Trifilieff, E. (2017). Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1707925114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.